2-(P-Aminobenzenesulfonamido)Thiazole

Injectable Solution Sterility Assurance and Sodium Salt Dissociation Behaviour

Preparation of a parenteral-grade solution from 2-(p-aminobenzenesulfonamido)thiazole mandates conversion to the sodium salt in situ, as the free acid exhibits aqueous solubility below 0.6 mg/mL at 25°C. In a jacketed 316L stainless steel compounding vessel purged with pharmaceutical-grade nitrogen, the active ingredient is suspended in Water for Injection at a ratio corresponding to 100 mg/mL sulfathiazole sodium equivalent, and 1 M sodium hydroxide solution is metered under continuous high-shear mixing until a stable pH of 10.0–10.5 is achieved — the narrow window above the compound’s pKa₂ of 7.1 at which ionisation suppresses free acid reprecipitation. A chelating agent, typically edetate disodium at 0.01% w/v, is introduced to sequester trace metal ions that catalyse oxidative colour development. The bulk solution is then treated with activated charcoal (0.1% w/v, pharmaceutical grade, acid-washed) and recirculated through a 0.45 µm polyethersulfone pre-filter to reduce endotoxin load before terminal sterilising-grade filtration through a validated 0.22 µm polyvinylidene fluoride membrane cartridge. Terminal steam sterilisation is precluded by the molecule’s thermal lability: forced degradation studies conducted per ICH Q1A(R2) demonstrate that exposure to 121°C saturated steam for 15 minutes results in 7–12% assay loss via hydrolysis of the sulfonamide bond, generating sulfanilic acid and 2-aminothiazole as primary degradants. Consequently, the entire process from dissolution to aseptic filling into Type I borosilicate vials must be conducted in an ISO Class 5 cleanroom environment. The finished product, Sulfathiazole Sodium Injection, is a clear, pale-yellow liquid intended for intravenous or intramuscular administration in cattle, swine, and sheep. Regulatory compliance is established against the monograph of the United States Pharmacopeia (Sulfathiazole Sodium Injection) and 21 CFR 522.2460, which stipulates an assay range of 95.0–105.0% of labelled content, a pH specification of 9.0–10.5, and a bacterial endotoxin limit of not more than 0.5 EU/mg. Post-sterilisation particulate monitoring must satisfy USP <788> limits for large-volume injections if the presentation exceeds 100 mL, with sub-visible particle counts controlled via light obscuration particle counting. Batch records routinely document osmolality targets of 580–620 mOsm/kg to minimise injection-site irritation, a critical quality attribute not harmonised across all pharmacopoeias but increasingly required by Canadian and EU competent authorities.

What Limits Suspension Physical Stability in High-Dose Drinking Water Dispersions?

When 2-(p-aminobenzenesulfonamido)thiazole is administered to poultry or swine via drinking water, the free acid form is micronised to a particle size distribution where 90% of the volume (Dv90) is less than 10 µm immediately prior to the dispersion stage. The objective is to formulate a pourable suspension concentrate containing 20–25% w/v active substance that, upon dilution in drinking water, delivers a therapeutic dose of 50–100 mg/kg bodyweight per day. Because sulfathiazole has a pronounced tendency to undergo Ostwald ripening in aqueous vehicles, the suspension is structured with a combination of microcrystalline cellulose-sodium carboxymethylcellulose co-processed thickener (1.5% w/v) and xanthan gum (0.15% w/v), which together generate a yield stress sufficient to retain a % suspended solids value above 95% after 48 hours. A nonionic surfactant blend of polysorbate 80 (0.05%) and sorbitan monooleate (0.01%) is pre-dispersed to lower the contact angle on the crystal surface and facilitate wetting when the powder is added to the mixing tank through an eductor funnel. Adjustment to a mildly alkaline pH of 8.2–8.8 with trisodium phosphate or sodium bicarbonate not only enhances chemical stability by shifting equilibrium away from the undissociated acid but also acts as a buffering preservative system in combination with sodium benzoate (0.1%), reducing the need for propylparaben in feeds compromised by high microbial load. The process train consists of an inline high-shear rotor-stator mixer operating at a tip speed of 18 m/s, followed by passage through a horizontal bead mill charged with 0.6–0.8 mm yttria-stabilised zirconia beads, targeting a median particle size (Dv50) of 2–4 µm. The final product is a water-dispersible liquid concentrate, commonly packaged in HDPE jerrycans with nitrogen blanket in the headspace, and labelled for dilution at 1 L per 1000 L of drinking water. Conformity is demonstrated according to the specifications of the European Pharmacopoeia general monograph “Oral Liquids for Veterinary Use” and the withdrawal period requirements of Commission Regulation (EU) No 37/2010, which sets the maximum residue limit for sulfonamides at 100 µg/kg in edible tissues. On-farm data consistently show that when waterlines have been previously treated with citric acid, the drop in pH to below 6.5 in the header tank can trigger massive sulfathiazole precipitation and line blockage, a constraint that mandates daily flushing protocols.

For large-scale prophylactic oral delivery through compounded feed, sulfathiazole is incorporated at a concentration of 100–200 g active ingredient per metric ton of complete feed, targeting control of respiratory pathogens such as Pasteurella multocida in swine. The manufacturing framework is a three-stage geometric dilution process that must comply with 21 CFR Part 225 (Current Good Manufacturing Practice for Medicated Feeds) and be executed on a dedicated production line to prevent cross-contamination with ionophores or macrolides, which can exhibit synergistic toxicity. An initial pre-blend of sulfathiazole powder with a food-grade excipient carrier — typically ground limestone with a bulk density of 1.0–1.4 g/cm³ or spray-dried corn starch with a moisture content below 8% — is prepared in a ribbon blender with an agitator speed of 40–60 rpm for 12 minutes. The pre-blend is then extended into a larger batch through a second blending step with a more voluminous carrier base such as calcium carbonate or pelleted wheat middlings, using a double-shaft paddle mixer validated to achieve a coefficient of variation (CV) of active content below 10%, as verified by near-infrared spectroscopy at 12 sampling points per tonne. The terminal blending stage integrates additional micronutrients or choline chloride; however, choline chloride loading must not exceed 300 mg/kg of the final mix because its hygroscopic character accelerates sulfonamide hydrolysis through local water activity increases. The final medicated premix is sieved through a 1.2 mm oscillating screen and directly bagged in multi-layer paper sacks with an inner polyethylene liner, with a shelf life truncated to 6 months when stored at ambient relative humidity above 60%. The finished premix type is registered under the product category “Medicated Premix” in accordance with Directive 2001/82/EC and the VICH GL18 guideline on residual solvents provides the analytical surveillance framework when methanol or acetone residues from earlier synthesis steps are detected above 0.1%.

When designing an intrauterine pessary for post-partum metritis in dairy cattle, the rate of drug release from a high-water-solubility urea matrix presents a formulation tension. 2-(p-aminobenzenesulfonamido)thiazole at 10–15% w/w is triturated with micronised urea (25–35% w/w) and polyethylene glycol 6000 and 1500 eutectic mixtures (45–55% w/w) to form a thermo-softening paste that is cast into torpedo-shaped moulds with a 50 g mass. The urea simultaneously serves as a hydrotropic agent that elevates sulfathiazole solubility in uterine fluids and as an osmotic desiccator that reduces bacterial biofilm adhesion. Homogeneity is confirmed by in-process sampling for assay via HPLC, with acceptance criteria of 90.0–110.0% of label claim per individual pessary. The manufacturing process entails melting the PEGs at 60–65°C in a planetary mixer, gradually sifting in the sulfathiazole-urea blend under vacuum (–0.85 bar), and injecting the melt into pre-lubricated aluminium moulds cooled to 5°C. The released solid pessaries are immediately sealed in trilaminate foil pouches with desiccant. As these products are non-sterile by design, microbiological quality is governed by USP <1111> for vaginal preparations: total aerobic microbial count <10² CFU/g, total combined yeasts and moulds <10¹ CFU/g, and absence of Pseudomonas aeruginosa and Staphylococcus aureus. A significant processing hazard arises if the molten mass is held above 70°C for longer than 90 minutes, whereupon sulfathiazole can react with urea to form an insoluble carbamate adduct, reducing bioavailable drug content and necessitating strict jacketed-zone temperature control with alarm interlocks.

Establishing a Validatable Sterility Assurance Level for Sulphonamide Dusting Powders

Crystalline 2-(p-aminobenzenesulfonamido)thiazole intended for application directly onto surgically debrided wounds or foot-rot lesions in small ruminants is processed into a sterile free-flowing powder containing 10–20% w/w active substance in an absorbable base. The base matrix is commonly sterilised maize starch or collagen-derived lyophilised powder, selected for its capillary wicking capacity and chloride content below 0.05%, since residual chlorides accelerate corrosion of metal packaging closures under tropical shipment conditions. Particle engineering is consequential: the sulfathiazole bulk is air-jet milled at a grinding pressure of 6 bar using a pancake mill, targeting a Dv90 of ≤15 µm, and then blended with the sterile excipient in a double-cone blender at 20 rpm for 30 minutes. Sterilisation is typically achieved by gamma irradiation at a dose of 25 kGy validated to achieve a sterility assurance level of 10⁻⁶, in accordance with ISO 11137-2:2013. Irradiation must be rigorously audited because sulfathiazole exhibits a G-value for free-radical generation sufficient to produce trace sulfanilamide and SO₂ volatiles at doses above 30 kGy, detectable by ion chromatography and olfactory panel respectively. An alternative ethylene oxide cycle validated to EN 1422:2014 using a 600 mg/L gas concentration at 55°C and 60% relative humidity is permissible only when a residue desorption step lasting not less than 72 hours at 35°C follows, driven by USP <1091> guidance on ethylene oxide residuals. The terminal product, a dusting powder in a puffer pack or LDPE squeeze bottle, carries a compendial requirement for non-sterile powders (USP <795>) when the package is not designated as a sterile barrier, or must meet the finished product test for sterility (USP <71>) if labelled as a sterile powder. The choice between the two classifications influences the entire supply chain, as non-sterile presentation requires no barrier packaging validation but imposes a caution label: “Not for application to deep or puncture wounds”.

Critical to direct compression of antimicrobial tablets for companion animals is the particle-level interplay between the micronised sulfathiazole (500 mg active per tablet), spray-dried lactose monohydrate (120 mg), microcrystalline cellulose (80 mg), crospovidone disintegrant (25 mg), and magnesium stearate (5 mg), which is added only in the final 3 minutes of blending to limit lubrication time. The 2-(p-aminobenzenesulfonamido)thiazole crystals exhibit a plate-like primary habit with a high aspect ratio that promotes lamination under compaction forces exceeding 15 kN; therefore, the compression profile is adjusted on a rotatory tablet press to a main compression force plateau of 9–12 kN, yielding tablets with a diametral crushing strength of 5–8 kp as measured per USP <1217>. Disintegration time is bracketed at 8–14 minutes in 900 mL of 0.1 M hydrochloric acid at 37°C, meeting the veterinary oral dosage form monograph tolerance of not more than 15 minutes. The dissolution test, performed using USP Apparatus II at 75 rpm in pH 1.2 medium, must report a Q value of not less than 80% dissolved at 45 minutes, though notable batch-to-batch variance arises when the sulfathiazole raw material particle size distribution shifts from the 50–100 µm specification. A process-analytical technology initiative based on in-line NIR monitoring of tablet content uniformity and disintegration is recommended under the enhanced QbD frameworks described in ICH Q8(R2), particularly where the tablets are co-administered with trimethoprim-containing boluses that alter gastric pH. The finished product, Sulfathiazole Tablets 500 mg, is an uncoated flat-faced bevel-edge tablet for oral dosing in dogs, with all excipients listed on the US FDA’s Index of Approved Inactive Ingredients for Veterinary Use and manufactured under the monitoring of 21 CFR 211 current good manufacturing practice for finished pharmaceuticals.